Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618330 | 0.90 | GSK3B (0.44) | ADORA3ADORA2AADORA1SMN1; SMN2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27564785 | 0.88 | GSK3B (0.43) | ADORA3ADORA2AADORA1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11297462 | 0.87 | GPR84 (0.44) | ADORA3ADORA2AADORA1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2946753 | 0.87 | GPR84 (0.44) | ADORA3ADORA2AADORA1SMN1; SMN2ALDH1A1 | |
| SCHEMBL457222 | 0.85 | SMN1; SMN2 (0.56) | ADORA3ADORA2AADORA1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4814536 | 0.84 | GPR84 (0.42) | ADORA3ADORA2AADORA1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28173006 | 0.84 | TP53 (0.42) | ADORA3ADORA2AADORA1SMN1; SMN2SREBF2 | |
| SCHEMBL1919006 | 0.84 | GSK3B (0.49) | ADORA3ADORA2AADORA1PDE3BPDE3A | |
| SCHEMBL8012754 | 0.83 | SREBF2 (0.41) | ADORA3ADORA2AADORA1SMN1; SMN2SREBF2 | |
| SCHEMBL8723967 | 0.82 | NOTUM (0.39) | ADORA3ADORA2AADORA1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112908530-B | Power distribution copper core wire and wire core stranding device | 芜湖森普铁芯有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-3081213-B1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO LTD (JP) | 2020-04-01 | — | — | EP | disclosed |
| US-9475805-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| EP-3081213-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-20150291587-A1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20130267711-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8486980-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-07-16 | — | — | US | disclosed |
| US-20110201640-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2327690-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| EP-2327690-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010016549-A1 | TRICYCLIC COMPOUND | 協和発酵キリン株式会社 (JP) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291587-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | ADORA3 654/4885ADORA2A 596/4885ADORA1 450/4885 |
| US-20130267711-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | ADORA3 654/4885ADORA2A 596/4885ADORA1 450/4885 |
| US-20110201640-A1 | TRICYCLIC COMPOUND | PPARG, PPARA, PPARD | ADORA3 1519/4885ADORA2A 1624/4885ADORA1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.